Grid Therapeutics Selected by the NCI’s NExT Program to Complete the IND Enabling Nonclinical Work for GT103Read more
Grid Therapeutics Collaborates with Catalent to Develop the First Human-Derived Antibody for the Treatment of CancerRead more
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.
Winkler MT, Bushey RT, Gottlin EB, Campa MJ, Guadalupe ES, Volkheimer
AD, Weinberg JB, Patz EF Jr.
PLoS One. 2017 Jun 28;12(6):e0179841. doi:
10.1371/journal.pone.0179841. eCollection 2017.
PMID: 28658265 [PubMed – in process] Free PMC ArticleRead more